Zacks Investment Research upgraded shares of Apricus Biosciences Inc. (NASDAQ:APRI) from a sell rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ┬«. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT┬« drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California. “

Shares of Apricus Biosciences (NASDAQ:APRI) opened at 0.326 on Tuesday. The stock has a 50 day moving average price of $0.35 and a 200-day moving average price of $0.40. The firm’s market capitalization is $21.63 million. Apricus Biosciences has a 52-week low of $0.28 and a 52-week high of $1.55.

Apricus Biosciences (NASDAQ:APRI) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. During the same period last year, the company earned ($0.10) earnings per share. Equities analysts forecast that Apricus Biosciences will post ($0.17) EPS for the current year.

An institutional investor recently raised its position in Apricus Biosciences stock. Vanguard Group Inc. boosted its position in Apricus Biosciences Inc. (NASDAQ:APRI) by 0.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,511,841 shares of the company’s stock after buying an additional 9,786 shares during the period. Vanguard Group Inc. owned approximately 2.44% of Apricus Biosciences worth $604,000 as of its most recent filing with the SEC. 23.83% of the stock is owned by hedge funds and other institutional investors.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

5 Day Chart for NASDAQ:APRI

Receive News & Stock Ratings for Apricus Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc. and related stocks with our FREE daily email newsletter.